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Tracking the Impact of Diseases of Despair in Appalachia—2015 to 2018
Abstract
Introduction
Introduction: This study provides an update on mortality due to diseases of despair within the
Appalachian Region, comparing 2015 to 2018.
Methods
Methods: Diseases of despair include: alcohol, prescription drug and illegal drug overdose, suicide, and
alcoholic liver disease/cirrhosis of the liver. Analyses are based on National Vital Statistics System
(NVSS) mortality data for individuals aged 15-64.
Results
Results: Between 2015 and 2017, the diseases of despair mortality rate increased in both Appalachia and
the non-Appalachian U.S., and the disparity grew between Appalachia and the rest of the county. In 2018,
the disease of despair mortality rate declined by 8 percent in Appalachia, marking the first decline for the
Region since 2012. Diseases of despair continue to impact the working-age population, and while males
experience a higher burden of mortality due to diseases of despair, the disparity between Appalachia and
the rest of the United States is greater for females. Overdose mortality rates in Appalachia increased
between 2015 and 2017, followed by a decline in 2018. During this same time frame, suicide also
increased notably within the Appalachian region, and the disparity between Appalachia and the nonAppalachian U.S. increased by 50 percent.
Implications
Implications: These findings document that the diseases of despair continue to have a greater impact in
the Appalachian Region than in the rest of the United States. While the declining trends between 2017 and
2018 are promising, data has shown that these rates are likely to increase again, particularly as a result of
the COVID-19 pandemic.
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INTRODUCTION

T

he concept of diseases or deaths of despair originated from research by
Case and Deaton1 that highlighted rising morbidity and mortality among
white non-Hispanic Americans from three main causes: alcoholic,
prescription drug, and illegal drug overdose; suicide; and alcohol liver
disease/cirrhosis of the liver. The initial Case and Deaton article was published
in 2015, at a time when life expectancy in the U.S. fell for the first time in
decades, and many researchers began to hypothesize what may be contributing
to this decline. This also marked the beginning of the surge in drug overdose
deaths in the U.S., driven by rapid increases in deaths from synthetic opioids,
such as fentanyl.2
In 2017, NORC at the University of Chicago (NORC) conducted a study on behalf
of the Appalachian Regional Commission (ARC) to further understand how the
diseases of despair may have disproportionately impacted the Appalachian
Region.3 In this study, NORC identified many disparities between the
Appalachian Region and the non-Appalachian U.S., most notably in terms of
overdose mortality. Specifically, in 2015, the overdose mortality rate was 65%
higher in the Appalachian Region compared to the non-Appalachian U.S.3
However, the initial study was based on mortality data through 2015, and
therefore did not reflect the more recent trends in drug overdose mortality.
In 2019, NORC published findings from the initial diseases of despair study,
predominately based on mortality data from 2015, but with the addition of some
more recent 2017 mortality data.4 The burden of diseases of despair in both
Appalachia and across the U.S. continued to rise through 2017. The current
paper provides an update to the original research on diseases of despair in
Appalachia, including mortality data through 2018. The findings compare 2015
and 2018 data in order to show where disparities have shifted during this time
period. As we continue to understand how the diseases of despair impact the
Appalachian Region, it will help the allocation of resources to address the root
causes of these deaths.

METHODS
Similar to the prior study on diseases of despair in Appalachia, this study aimed
to detect differences in the mortality rates from diseases of despair between the
Appalachian Region and the non-Appalachian U.S. (the rest of the country,
excluding Appalachia), in addition to differences by age groups and gender.
Appalachian rates were further analyzed by subregion, county economic status,
and levels of rurality. Appalachian subregions, as defined by the Appalachian
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Regional Commission (ARC), represent contiguous geographies of relatively
homogeneous characteristics (topography, demographics, economics, and
transportation) and include: Northern, North Central, Central, South Central,
and Southern Appalachia. ARC also provides county-level economic
classifications based on an index of three economic indicators (3-year
unemployment rate, per capita market income, and poverty rate). Counties are
designated based on the index as distressed, at-risk, transitional, competitive,
or attainment.5 Last, ARC designations for rurality were used for these analyses.
These designations of large metro, small metro, nonmetro adjacent to large
metros, nonmetro counties adjacent to small metros, and rural counties are
based on a simplification of the UDSA’s Economic Research Services (ERS) 2013
Urban Influence Codes (UIC).6
The majority of the findings presented are from 2018 mortality data from the
National Center for Health Statistics (NCHS) National Vital Statistics System
(NVSS) Multiple Cause of Death database, accessed through the CDC Wideranging Online Data for Epidemiologic Research (CDC WONDER).7 Comparisons
to 2015 mortality data are also included. The Multiple Cause of Death database
provides the underlying cause of death, as well as up to 20 additional multiple
causes, as reported on an individual’s death certificate by a physician, coroner,
and/or medical examiner.8 Deaths are coded to the International Classification
of Disease Tenth Revision (ICD-10) codes.
These analyses included the ICD-10 codes referenced by Case and Deaton,1
reflecting the underlying cause of death from each of the three diseases of
despair: alcohol, prescription drug, and illegal drug overdose (X40–X45, Y10–
Y15, Y45–Y49); suicide (Y87.0, X60–X84); and alcoholic liver disease/cirrhosis
of the liver (K70, K73–K74). Multiple cause-of-death ICD–10 codes (T40.0, T40.1,
T40.2, T40.3, T40.4, T40.6) that specify the type of drug causing the overdose
were used to determine the percentage of alcohol, prescription drug, and illegal
drug overdose deaths attributed to opioids.9 The findings present age-adjusted
mortality rates for the population aged 15 to 64. Statistical significance was
assessed at the 0.05 level using two-sided significance tests (z-tests).

RESULTS
Over the past 2 decades, the mortality rate due to diseases of despair has been
increasing across the U.S. Between 2015 and 2017, the mortality rate increased
notably across the country, and the gap between the Appalachian Region and
non-Appalachian U.S. continued to widen. As shown in Figure 1, the diseases of
despair mortality rate in the Appalachian Region increased by 24% between 2015
and 2017, compared to an increase of 17% for the non-Appalachian U.S. In 2017,
https://uknowledge.uky.edu/jah/vol3/iss2/6
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the diseases of despair mortality rate was 45% higher in Appalachia than the
non-Appalachian U.S. However, 2018 showed the first decline in diseases of
despair mortality for the Appalachian Region since 2012. Within the Appalachian
Region, the diseases of despair mortality rate decreased by approximately 8%
between 2017 and 2018.

Figure 1. Annual Mortality Rates Attributable to Diseases of
Despair, Ages 15–64, by Region (1999–2018)*‡
‡Rates are presented as deaths per 100,000 population. Rates are age-adjusted.
*In all years except 1999, the Appalachian rate is significantly different from the nonAppalachian U.S. rate, p ≤0.05
Source: Mortality Rates and Standard Errors provided by Centers for Disease Control
and Prevention, National Center for Health Statistics.
Accessed at http://wonder.cdc.gov/mcd-icd10.html

The burden of diseases of despair mortality and the disparity between
Appalachia and the non-Appalachian U.S. is particularly notable for the
working-age population (individuals aged 25 to 54). As shown in Figure 2, in
2018, the diseases of despair mortality rate for males aged 25 to 54 was 121.2
deaths per 100,000 in Appalachia and 88.0 deaths per 100,000 in the nonAppalachian U.S. For females aged 25 to 54, the diseases of despair mortality
rate was 55.6 deaths per 100,000 in Appalachia, compared to 35.8 deaths per
100,000 in the non-Appalachian U.S. While the burden of diseases of despair
mortality for males was more than double that of females in the Appalachian
Region, the disparity between the Appalachian Region and non-Appalachian U.S.
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was wider for females. The mortality rate among females was 55% greater in the
Appalachian Region than the non-Appalachian U.S, and the mortality rate
among males was 38% higher in the Appalachian Region than the nonAppalachian U.S.
121.2
88.0
55.6
35.8

Males

Females
Appalachia

Non-Appalachian U.S.

Figure 2. Annual Mortality Rates Attributable to Diseases of
Despair, Ages 25–54, by Region (2018)*‡
‡Rates are presented as deaths per 100,000 population. Rates are age-adjusted.
*For both genders, Appalachian rate is significantly different from the nonAppalachian U.S. rate, p ≤0.05.
Source: Mortality Rates and Standard Errors provided by Centers for Disease Control
and Prevention, National Center for Health Statistics.
Accessed at http://wonder.cdc.gov/mcd-icd10.html

Table 1 compares the 2018 mortality rates to 2015 mortality rates for overdose,
suicide, and alcoholic liver disease/cirrhosis for various subgroups. In 2015, the
overdose mortality rate among those aged 15 to 65 years in Appalachia was 65%
greater than the non-Appalachian U.S. (35.4 deaths per 100,000 population
compared to 21.5 deaths per 100,000 population). For both the Appalachian
Region and the non-Appalachian U.S., the overdose mortality rate increased
between 2015 and 2018; however, the disparity between Appalachia and the
non-Appalachian U.S. decreased. In 2018, the overdose mortality rate was 48%
greater in Appalachia than the non-Appalachian U.S. (41.6 deaths per 100,000
population compared to 28.1 deaths per 100,000 population. Between 2015 and
2018, the overdose mortality rates increased across all subregions of
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Table 1. Diseases of Despair Mortality Rates (2018 vs. 2015), ages 15–64‡
Overdose

Suicide

Alcoholic liver
disease/cirrhosis

2015

2018

2015

2018

2015

2018

Appalachia

35.4

41.6

19.8

22.7

11.4

12.0

Non-Appalachian U.S.

21.5

28.1

16.5

17.5

10.6

10.6

Northern

40.2

49.9

19.7

22.0

9.3

9.4

North Central

56.3

69.8

19.4

26.9

13.0

13.1

Central

54.9

52.3

23.3

24.1

16.2

17.7

South Central

30.7

41.2

21.1

23.3

13.3

15.6

Southern

22.7

24.0

18.5

21.6

11.0

10.7

Distressed

46.2

48.5

22.1

25.1

15.4

18.2

Nondistressed

34.6

41.2

19.6

22.3

11.2

11.6

Metro

36.1

43.5

18.8

21.5

11.0

11.1

Nonmetro

33.8

37.8

21.7

25.2

12.4

13.7

Male

45.1

53.6

31.1

35.4

16.0

16.6

Female

25.6

29.6

8.5

10.0

7.0

7.5

15–24

12.3

13.6

12.6

16.9

--

--

25–34

44.5

53.5

19.4

23.6

1.7

1.8

35–44

47.8

61.6

21.9

24.4

8.3

8.4

45–54

42.7

42.9

24.5

25.0

21.8

22.8

55–64

23.2

28.3

20.7

23.7

34.5

36.6

Region

Appalachian Subregion

Economic Status in
Appalachia

Rurality (within
Appalachia)

Gender (within
Appalachia)

Age Group (within
Appalachia)*

‡Rates are presented as deaths per 100,000 population. Rates are age-adjusted.
*Crude mortality rates are reported.
Source: Mortality Rates and Standard Errors provided by Centers for Disease Control and
Prevention, National Center for Health Statistics.
Accessed at http://wonder.cdc.gov/mcd-icd10.html

Appalachia except Central Appalachia, where the overdose mortality rate
declined from 54.9 deaths per 100,000 population to 52.3 deaths per 100,000
population. While the overdose mortality rate declined between the two time
periods in Central Appalachia, several other subregions within Appalachia saw
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significant increases in overdose mortality. Between 2015 and 2018, the
overdose mortality rate in Northern, North Central, and South Central
Appalachia increased by at least 20%. North Central Appalachia had the highest
drug overdose mortality rate in 2018 of the five Appalachian subregions – 69.8
deaths per 100,000 population, which was almost 2.5 times the nonAppalachian U.S. overdose mortality rate. In 2018, overdose mortality continued
to be greater in economically distressed counties than nondistressed counties
and in metro counties than nonmetro counties. The group aged 35–44 years
experienced the largest rise in overdose mortality, increasing by 29% between
2015 (47.8 deaths per 100,000 population) and 2018 (61.6 deaths per 100,000
population).
While the burden associated with suicide is lower than that of overdose mortality,
the disparity between Appalachia and the non-Appalachian U.S. grew between
2015 and 2018. Specifically, in 2018, the suicide mortality rate was 30% higher
in Appalachia (22.7 deaths per 100,000 population) than the non-Appalachian
U.S. (17.5 deaths per 100,000 population). Only 3 years prior, in 2015, the
suicide mortality rate was 20% higher in Appalachia (19.8 deaths per 100,000
population) than the non-Appalachian U.S. (16.5 deaths per 100,000
population). While suicide rates increased in both the Appalachian Region and
non-Appalachian U.S. between 2015 and 2018, the rate increased more quickly
in Appalachia. This increase was driven by North Central Appalachia, where the
suicide rate increased by 39% between 2015 and 2018. By comparison, the
suicide rate in the other four subregions of Appalachia increased by less than
20%. In 2018, within Appalachia, the suicide mortality rates continued to be
higher among economically distressed counties and nonmetro counties. The
suicide mortality rate increased by the highest percentage between 2015 and
2018 for the groups aged 15 to 24 years and those aged 25 to 34 years. Among
the youngest population, individuals aged 15 to 24, the suicide mortality rate
increased by 34% between 2015 and 2018.
For alcoholic liver disease/cirrhosis, the mortality rate remained fairly constant
between 2015 and 2018; however, certain subregions experienced a greater
increase in mortality and the disparity grew within the Appalachian Region
among specific subpopulations. The alcoholic liver disease/cirrhosis mortality
rate increased by 17% in South Central Appalachia, which was the largest
percentage increase of any subregion between 2015 and 2018. Additionally, the
disparity between distressed and nondistressed counties and nonmetro and
metro counties continued to grow. In 2015, the mortality rate in distressed
counties was 38% higher than in nondistressed counties, and by 2018, this
difference grew to 57%: 18.2 deaths per 100,000 population for distressed
counties, compared to 11.6 deaths per 100,000 for nondistressed counties. In
https://uknowledge.uky.edu/jah/vol3/iss2/6
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2015, the mortality rate in nonmetro counties was 13% higher than in metro
counties, and by 2018, this difference grew to 23%: 13.7 deaths per 100,000
population fir nonmetro counties, compared to 11.1 deaths per 100,000 for
metro counties.
As shown in Figure 3, the overall burden and distribution of diseases of despair
mortality differ by state. In 2018, West Virginia, Appalachian Maryland, and
Appalachian Ohio had the highest overall diseases of despair mortality rates, in
addition to the highest overdose mortality rates. The suicide mortality rate was
highest in West Virginia, Appalachian Virginia, and Appalachian Ohio. The liver
disease mortality rate was highest in Appalachian Kentucky, Appalachian
Tennessee, and Appalachian Virginia.

Figure 3. Diseases of despair mortality by state^, aged 15–64
(2018)‡
^For states within Appalachia, only the mortality rate for the Appalachian counties is
shown.
‡Rates are presented as deaths per 100,000 population. Rates are age-adjusted.
Source: Mortality Rates and Standard Errors provided by Centers for Disease Control
and Prevention, National Center for Health Statistics.
Accessed at http://wonder.cdc.gov/mcd-icd10.html
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IMPLICATIONS
These findings provide an update to prior research on the scale and scope of the
impact of the diseases of despair in Appalachia. The Appalachian Region
continues to face disparities in terms of mortality from overdose, suicide, and
alcoholic liver disease/cirrhosis. Overdose mortality rates increased in
Appalachia between 2015 and 2017, followed by a decline in 2018.10 The
increase in overdose mortality between 2015 and 2017 in Appalachia aligns with
the time period where deaths from synthetic opioids increased rapidly in the
U.S.2 In 2018, the decline in overdose mortality in the U.S. was largely driven by
the decrease in prescription opioid-involved mortality.11 Between 2017 and 2018,
both West Virginia and Kentucky, which are included in Central Appalachia, saw
declines in opioid overdose mortality rates.11 Central Appalachia was the only
Appalachian subregion that did not see an increase in overdose mortality
between 2015 and 2018. During this same time period, North Central Appalachia
experienced a notable increase in overdose mortality, likely driven by deaths from
synthetic opioids, such as fentanyl. Suicide rates also increased notably within
the Appalachian region between 2015 and 2018, and the disparity between
Appalachia and the non-Appalachian U.S. increased by 50%.
These disparities are not evenly distributed across the Appalachian regions, and
certain Appalachian subpopulations experience greater burden. In particular,
the working-age population (individuals aged 25 to 54) in Appalachia faces some
of the greatest disparities compared to the non-Appalachian U.S, which has
implications for economic development within the region. Disparities within
Appalachia have grown among economically distressed and nonmetro counties,
and women in Appalachia face greater disparities across diseases of despair as
compared to Appalachian men, though mortality rates remain higher for
Appalachian men.
While the 2018 data showed declines in diseases of despair mortality for both
Appalachia and the non-Appalachian U.S., we anticipate that these
improvements will be short-lived, particularly as the impacts of the COVID-19
pandemic are observed in the data. Provisional data from CDC indicate that
overdose deaths have accelerated during the COVID-19 pandemic and, in the 12
months ending in May 2020, the U.S. had over 81,000 drug overdose deaths,
which was the highest number ever recorded in a 12-month period.12 One major
limitation to this study is the fact that it is based on 2018 mortality data. When
the study was conducted, 2018 was the most recent year of mortality available
from CDC WONDER, therefore, the trends have likely shifted over the past
several years. In particular, the impact of the COVID-19 pandemic is not

https://uknowledge.uky.edu/jah/vol3/iss2/6
DOI: https://doi.org/10.13023/jah.0302.06

65

Heffernan et al.: Tracking the Impact of Diseases of Despair in Appalachia—2015 to 2018

reflected in these findings. Additional research will be needed to determine both
short and long-term impacts of the COVID-19 pandemic on diseases of despair
mortality.

SUMMARY BOX
What is already known on this topic? Prior research has shown the disparity
between the Appalachian Region and the non-Appalachian U.S. in terms of
diseases of despair mortality.
What is added by this report? This article provides an update to initial
findings and compares 2015 to 2018 mortality rates. This report shows
increasing diseases of despair mortality rates between 2015 and 2017, followed
by a decline in 2018. Disparities continue to exist between Appalachia and the
rest of the country.
What are the implications for further research? Further research is needed
to determine the impact of the COVID-19 pandemic on diseases of despair
mortality, particularly in areas like Appalachia that have been impacted
significantly by the diseases of despair.
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